U.S. Clarity Act failure gives Asia and Middle East a competitive edge, says Ape...
Apex Group CEO Peter Hughes warned that the failure of the U.S. Clarity Act will drive digital asset businesses toward faster-movi...
Bitcoin Core Speeds Up Bug Fixes As AI Changes Disclosure Rules
A change to Bitcoin Core’s security policy makes rapid patch releases the priority when keeping a vulnerability secret offers litt...
DeepBook Protocol Price Prediction 2026, 2027 – 2030: Is DEEP a Good Investment?
The post DeepBook Protocol Price Prediction 2026, 2027 – 2030: Is DEEP a Good Investment? appeared first on Coinpedia Fintech News...
Serum Price Prediction 2026,2027-2030: Is SRM Still Worth Holding?
The post Serum Price Prediction 2026,2027-2030: Is SRM Still Worth Holding? appeared first on Coinpedia Fintech NewsStory Highlig...
US Tech Stocks Under Pressure: 3 Stocks to Watch Before Next Week’s Earnings
The post US Tech Stocks Under Pressure: 3 Stocks to Watch Before Next Week’s Earnings appeared first on Coinpedia Fintech NewsUS...
Arweave (AR) Price Prediction 2026, 2027-2030: Can AR Rally to $6 This Year?
The post Arweave (AR) Price Prediction 2026, 2027-2030: Can AR Rally to $6 This Year? appeared first on Coinpedia Fintech NewsSto...
Bloomberg Adds Basel Crypto Exposure Classification For Banks And Asset Managers
Bloomberg has expanded its crypto analytics to classify bank exposure under Basel standards, including indirect holdings hidden in...
Conflux Price Prediction 2026, 2027 – 2030: Will CFX Price Hit $1?
The post Conflux Price Prediction 2026, 2027 – 2030: Will CFX Price Hit $1? appeared first on Coinpedia Fintech NewsStory Highlig...
Pendle Price Prediction 2026, 2027 – 2030: Is PENDLE Coin Worth A Buy?
The post Pendle Price Prediction 2026, 2027 – 2030: Is PENDLE Coin Worth A Buy? appeared first on Coinpedia Fintech NewsStory Hig...
BeOne Medicines AG (ONC) Stock: 36% Liver Cancer Response Rate Fuels Breakthroug...
TLDR BeOne’s liver cancer drug posts a 36% response rate in a Phase 1 clinical study. BGB-B2033 shows a 74.1% six-month response d...